(PharmaNewsWire.Com, June 08, 2017 ) Cystic fibrosis (CF) is an inherited disorder that affects the cells that produce mucus, sweat, and digestive juices, causing severe damage to the lungs, digestive system, and other organs. In CF patients, a defective gene results in sticky and thick secretions that plug up tubes, ducts, and passageways. The signs and symptoms of CF vary depending on the severity of the disease. Most of the signs and symptoms of CF affect the respiratory system and digestive system.
Publisher epidemiologists provided two different forecasts for the diagnosed incident and diagnosed prevalent cases of CF in the 7MM: a forecast based on registry data and a forecast adjusted for the underestimation of registry-based data. According to the forecast based on registry data, the diagnosed incident cases of CF in the 7MM will decrease from 1,925 cases in 2015 to 1,813 cases in 2025, at an Annual Growth Rate (AGR) of negative 0.58%. The US will have the highest number of diagnosed incident cases of CF among the 7MM throughout the forecast period, while Germany will have the lowest.
According to the forecast adjusted for underestimation of registry data, the diagnosed incident cases of CF in the 7MM will decrease from 2,217 cases in 2015 to 2,074 cases in 2025, at an AGR of negative 0.64%. The US will have the highest number of diagnosed incident cases of CF among the 7MM throughout the forecast period, while Germany will have the lowest.
Publisher epidemiologists utilized peer-reviewed, country-specific studies to forecast diagnosed incident cases, diagnosed prevalent cases, and mortality due to CF in the 7MM from 2015-2025. Diagnosed prevalent cases were segmented by sex, age, specific mutation type, and MRSA infection to provide more detailed information about the patient population. Publisher epidemiologists ensured that the forecast methodology was consistent across all the 7MM to allow for a meaningful comparison of CF across these markets.
Scope
- The Cystic Fibrosis (CF) EpiCast Report provides an overview of the risk factors and global trends of CF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Canada) . It includes a 10-year epidemiology forecast of diagnosed incident cases of CF, diagnosed prevalent cases of CF, and CF mortality segmented by sex in these seven markets. Diagnosed prevalent cases of CF are further segmented by age (starting from zero years of age and up to 85 years and older) , specific mutation type, and chronic Methicillin-resistant Staphylococcus aureus (MRSA) infection. - The CF epidemiology report is written and developed by Masters- and PhD-level epidemiologists. - The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
The CF EpiCast series will allow you to - - Develop business strategies by understanding the trends shaping and driving the global CF market. - Quantify patient populations in the global CF market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CF therapeutics in each of the markets covered. - Identify the percentage of CF diagnosed prevalent cases by age, sex, specific mutation type, and MRSA infection. Table of Content: 1.1 List of Tables 3 1.2 List of Figures 4 2 Executive Summary 5 2.1 Related Reports 12 3 Epidemiology 13 3.1 Disease Background 13 3.2 Risk Factors and Comorbidities 14 3.3 Global Trends 15 3.3.1 Diagnosed Incidence and Diagnosed Prevalence 16 3.4 Forecast Methodology 18 3.4.1 Sources Used 18 3.4.2 Forecast Assumptions and Methods 25 3.4.3 Sources Not Used 34 3.5 Epidemiological Forecast for CF (2015-2025) 35 3.5.1 Diagnosed Incident Cases, Based on Registry Data 35 3.5.2 Diagnosed Prevalent Cases, Based on Registry Data 38 3.5.3 CF Mortality, Based on Registry Data 46 3.5.4 Diagnosed Incident Cases, Adjusted for Underestimation 49 3.5.5 Diagnosed Prevalent Cases, Adjusted for Underestimation 52 3.5.6 CF Mortality, Adjusted for Underestimation 59 3.6 Discussion 62 3.6.1 Epidemiological Forecast Insight 62 3.6.2 Limitations of the Analysis 63 3.6.3 Strengths of the Analysis 64 4 Appendix 65 4.1 Bibliography 65 4.2 Physicians and Specialists Included in this Study 67 4.3 High-Prescribing Physician Survey 69 4.4 About the Authors 69 4.4.1 Epidemiologist 69 4.4.2 Reviewers 70 4.4.3 Global Director of Therapy Analysis and Epidemiology 71 4.4.4 Global Head of Healthcare 71 4.5 About Publisher 72 4.6 About EpiCast 72 4.7 Contact Us 73 4.8 Disclaimer 73 Inquire for Report at http://www.reportsweb.com/inquiry&RW0001766071/buying
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
